A Phase 1b/2 Open-Label Study With Randomization in Phase 2 of IMU-131 HER2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction
Latest Information Update: 05 Jun 2024
At a glance
- Drugs IMU 131 (Primary) ; Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms HERIZON
- Sponsors Imugene
- 10 Apr 2024 Results assessing safety and efficacy of HER-Vaxx plus chemotherapy to chemotherapy alone in patients with HER2-overexpressing gastric/gastro-esophageal junction (GC) cancer presented at the 115th Annual Meeting of the American Association for Cancer Research
- 09 Apr 2024 According to an Imugene media release, final results from this study were presented at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
- 09 Apr 2024 Results published in the Media Release